US 12,226,420 B2
Theramutein modultors
Gerard M. Housey, Southfield, MI (US)
Assigned to HMI MEDICAL INNOVATIONS, LLC, Southfield, MI (US)
Filed by HMI MEDICAL INNOVATIONS, LLC, Southfield, MI (US)
Filed on Feb. 6, 2024, as Appl. No. 18/433,881.
Application 17/857,478 is a division of application No. 17/038,353, filed on Sep. 30, 2020, granted, now 11,504,377, issued on Nov. 22, 2022.
Application 15/789,476 is a division of application No. 15/399,543, filed on Jan. 5, 2017, granted, now 9,795,610, issued on Oct. 24, 2017.
Application 15/399,543 is a division of application No. 14/297,863, filed on Jun. 6, 2014, granted, now 9,579,326, issued on Feb. 28, 2017.
Application 18/433,881 is a continuation of application No. 17/857,478, filed on Jul. 5, 2022, granted, now 11,925,647.
Application 17/038,353 is a continuation of application No. 16/656,271, filed on Oct. 17, 2019, granted, now 10,806,738, issued on Oct. 20, 2020.
Application 16/656,271 is a continuation of application No. 15/789,476, filed on Oct. 20, 2017, granted, now 10,471,065, issued on Nov. 12, 2019.
Application 14/297,863 is a continuation of application No. 13/758,422, filed on Feb. 4, 2013, abandoned.
Application 13/758,422 is a continuation of application No. 10/569,315, granted, now 8,367,038, issued on Feb. 5, 2013, previously published as PCT/US2005/018412, filed on May 23, 2005.
Claims priority of provisional application 60/633,013, filed on Dec. 3, 2004.
Claims priority of provisional application 60/573,962, filed on May 23, 2004.
Prior Publication US 2024/0180916 A1, Jun. 6, 2024
Int. Cl. A61K 31/5377 (2006.01); A61K 31/166 (2006.01); A61K 31/175 (2006.01); A61K 31/195 (2006.01); A61K 31/27 (2006.01); A61K 31/415 (2006.01); A61K 31/4196 (2006.01); A61K 31/44 (2006.01); A61K 31/4436 (2006.01); A61K 31/444 (2006.01); A61K 31/47 (2006.01); A61K 31/4709 (2006.01); A61K 31/495 (2006.01); A61K 31/505 (2006.01); A61K 31/506 (2006.01); A61K 31/517 (2006.01); A61K 31/53 (2006.01); C07C 243/38 (2006.01); C07D 213/77 (2006.01); C07D 213/81 (2006.01); C07D 213/86 (2006.01); C07D 213/87 (2006.01); C07D 215/38 (2006.01); C07D 215/50 (2006.01); C07D 231/14 (2006.01); C07D 239/42 (2006.01); C07D 239/48 (2006.01); C07D 239/84 (2006.01); C07D 253/065 (2006.01); C07D 253/075 (2006.01); C07D 401/12 (2006.01); C07D 403/12 (2006.01); C07D 405/12 (2006.01); C07D 409/12 (2006.01); G01N 33/50 (2006.01); G01N 33/573 (2006.01); G01N 33/574 (2006.01)
CPC A61K 31/5377 (2013.01) [A61K 31/166 (2013.01); A61K 31/175 (2013.01); A61K 31/195 (2013.01); A61K 31/27 (2013.01); A61K 31/415 (2013.01); A61K 31/4196 (2013.01); A61K 31/44 (2013.01); A61K 31/4436 (2013.01); A61K 31/444 (2013.01); A61K 31/47 (2013.01); A61K 31/4709 (2013.01); A61K 31/495 (2013.01); A61K 31/505 (2013.01); A61K 31/506 (2013.01); A61K 31/517 (2013.01); A61K 31/53 (2013.01); C07C 243/38 (2013.01); C07D 213/77 (2013.01); C07D 213/81 (2013.01); C07D 213/86 (2013.01); C07D 213/87 (2013.01); C07D 215/38 (2013.01); C07D 215/50 (2013.01); C07D 231/14 (2013.01); C07D 239/42 (2013.01); C07D 239/48 (2013.01); C07D 239/84 (2013.01); C07D 253/065 (2013.01); C07D 253/075 (2013.01); C07D 401/12 (2013.01); C07D 403/12 (2013.01); C07D 405/12 (2013.01); C07D 409/12 (2013.01); G01N 33/5011 (2013.01); G01N 33/502 (2013.01); G01N 33/5041 (2013.01); G01N 33/573 (2013.01); G01N 33/574 (2013.01); G01N 2500/00 (2013.01); G01N 2500/10 (2013.01)] 21 Claims
 
1. A method for identifying and obtaining an inhibitor or activator of a theramutein from a first collection of compounds, wherein the theramutein is capable of eliciting a detectable phenoresponse and the theramutein has a corresponding prototheramutein, the method comprising:
(a) identifying a first subset of the first collection of compounds, the first subset of compounds comprising compounds that affect growth of a cell expressing the theramutein,
(b) rank ordering a second subset of the first subset of compounds into a rank-ordered list, the compounds of the second subset of compounds being rank-ordered based on their ability to affect growth of a cell expressing the theramutein;
(c) testing individual compounds of the second subset of compounds by comparing
(i) the phenoresponse obtained when contacting an individual compound with a respective test cell expressing the theramutein with
(ii) the phenoresponse obtained when contacting the individual compound with a control cell expressing the prototheramutein; and
(d) identifying a compound of the second subset of compounds as an inhibitor or activator of the theramutein based on results obtained in step (c).